SIGA Technologies, Inc. announced approximately $13 million of procurement orders for oral TPOXX (tecovirimat), including $11 million for initial procurement from two new international jurisdictions and an approximate $2 million order from a country in the Asia Pacific region that has an established contract for oral TPOXX (tecovirimat). The orders from the new international jurisdictions represent the first procurements of oral TPOXX (tecovirimat) directly in response to the evolving global monkeypox outbreak. One of the new jurisdictions is located in Europe and the other is located in the Asia Pacific region.

SIGA currently expects to deliver approximately $4 million of oral TPOXX (tecovirimat) under the two new contracts within the next 45 days. The remaining approximately $7 million of oral TPOXX (tecovirimat) is expected to be delivered in 2023. With respect to the order from an existing customer, SIGA recently fulfilled the order by delivering $2 million of oral TPOXX (tecovirimat).

In combination with a delivery of a previously disclosed order of $2.8 million, SIGA has delivered in total approximately $5 million of oral TPOXX (tecovirimat) to this country during this quarter.